Informação do artigo
Suplemento especial
AML itself is one of the worst prognostic hematological malignancies which has to be managed timely, adequately and aggressively to get on top of it. Such, kind of patients will need intensive chemotherapy therapy (3+7, Flag IDA) followed by allogeneic SCT. That is why it is challenging to manage such cases in resource limited setting. Due to constant development of new drugs treatment of such patients with azacytidine and venetoclax have been lot easier. With these drugs we are being able to put patients in remission with less toxicities, and low cost as compared to intensive chemotherapy.
O texto completo está disponível em PDF
